Medincell S.A.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00M0C8GJ0
MEDCL
Medincell S.A.
GICS: -
·
Sektor: -
·
Sub-Sektor: -
NAME
Medincell S.A.
ISIN
FR0004065605
TICKER
MEDCL
MIC
XPAR
REUTERS
MEDCL.PA
BLOOMBERG
MEDCL FP
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 12.12.2024
Medincell
FR0004065605
Medincell (Paris:MEDCL) joins the Euronext SBF 120 index, which includes the 120 largest companies listed on Euronext Paris, including the CAC 40 and most of the key players in the French economy. Medincell joins also the CAC Mid 60 index.
Christophe Douat, CEO of Medincell, said: “Just six years after our IPO, Medincell joins the SBF 120, a rec...
Medincell
Mo., 09.12.2024
Medincell
FR0004065605
Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with F14/mdc-CWM (n=51) to those in the control group (n=57)1:
70% reduction in the number of opioid users at 3 months post-surg...
Medincell
Mi., 06.11.2024
Medincell
FR0004065605
ACCESS HERE THE COMPLETE PRESS RELEASE
Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today as part of its Q3 2024 results, the following information:
About UZEDY®
Updated 2024 Revenue Outlook: Increased from $80 million to $100 million
U.S. Revenues Year-to-Date 2024: $75 million
U.S. Revenues for Q3 2024: $35 million
M...
Medincell
Mo., 04.11.2024
Medincell
FR0004065605
Medincell (Paris:MEDCL):
ACCESS HERE THE COMPLETE PRESS RELEASE
TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable
Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia.
Findings demonstrate significant improvement in soci...
Medincell
Mo., 23.09.2024
Medincell
FR0004065605
New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified.
Perseris manufacturer announced in July 2024 the discontinuation of its commercial...
Medincell
Mo., 23.09.2024
Medincell
FR0004065605
Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in adult patients diagnosed with schizophrenia.
Richard Malamut, Chief Medical Officer of Medincell, said: “In addition to publishing the positive efficacy results for the primary and seconda...
Medincell
Do., 05.09.2024
Medincell
FR0004065605
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22nd Annual Global Healthcare Conference held yesterday that c.99% of the targeted injections for submission have been performed as of today (replay available here). Teva also confirmed that the full submission safety results a...
Medincell
Di., 03.09.2024
Medincell
FR0004065605
Collaboration with AbbVie
Initiation of preclinical and supportive CMC* work to advance LAI candidate into clinical development
Collaboration with Teva
UZEDY® (risperidone LAI)
Reaffirming revenue guidance for 2024 by Teva: c.$80 million
Exploring an additional indication for the treatment of Bipolar I Disorder in adults
Olanza...
Medincell
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
